/
QIAGEN N.V. is a Netherlands-based holding company and the leading global provider of Sample to Insight solutions that transform biological samples into valuable molecular insights. Founded in Germany in 1984, it specializes in technologies for isolating and processing DNA, RNA, and proteins from blood, tissue, and other materials, alongside assay technologies, bioinformatics software, and automation workflows for analysis. The company serves over 500,000 customers worldwide across molecular diagnostics for human healthcare, applied testing in forensics, veterinary, and food safety, pharmaceutical and biotech R&D, and academic life sciences research. With more than 500 core products including disposable kits, automated workstations, and testing agents, QIAGEN operates in over 130 countries, with key locations in Venlo, Netherlands; Hilden, Germany; and regional hubs in the US, China, and Singapore. Employing thousands globally and led by CEO Thierry Bernard, QIAGEN plays a pivotal role in advancing scientific discovery, disease diagnosis, and personalized medicine through innovative molecular tools. Its extensive acquisition history, including companies like Digene, Cellestis, and Verogen, has expanded its capabilities in diagnostics and bioinformatics. QIAGEN N.V. significantly contributes to the life sciences and healthcare sectors by enabling faster, more reliable molecular analysis.
$40.90
$0.25 (-0.61%)
Live · 05:22 PM
24.90% operating margin is above average. ROIC at 8.53%. Note that capital returns lag the margin, the business may be capital-intensive despite high margins.
Revenue grew 5.7%, steady but not accelerating. Free cash flow declined 11% despite revenue growth, conversion is weakening.
Free cash flow declined 11% versus the prior year, cash generation momentum has weakened.
21.1x earnings, 21.2x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.10B
▲ +5.7% YoY
Net Income (TTM)
$402M
▲ +408.3% YoY
Op. Margin
24.38%
▲ +14.8pp YoY
ROIC
8.53%
▲ +5.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$404M
▼ -11.0% YoY
Op. Cash Flow (TTM)
$627M
▲ +0.2% YoY
Net Debt
$713M
Cash & Equiv.
$1.10B
3Y CAGR: -0.8%
3Y CAGR: -7.5%
Continue Research
At a P/E of 21.1 and a price-to-free-cash-flow of 21.2, Qiagen (QGEN) trades above a two-stage DCF intrinsic value of about $30.08 per share, so at $40.90 the stock looks overvalued (26.4% above estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Qiagen scores 38/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 0.6%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $30.08 per share for QGEN, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $22.56. At today's $40.90, that puts the stock about 26.4% above estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Qiagen scores 38 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 24.4% operating margin and a 8.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Yes, Qiagen pays a regular dividend of about $0.26 per share per year (typically in quarterly installments), a yield of roughly 0.6% at the current price. That is a payout ratio of about 13.5% of earnings, so the dividend is amply covered by earnings. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For QGEN's full payout history, growth streak and dividend-safety score, see the dividends tab.
That depends on valuation and quality together, not either alone. QGEN currently trades above its estimated intrinsic value and scores 38/100 on quality (lower-quality). It also yields about 0.6%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.